REG - Creo Medical Group - Director/PDMR Shareholding

Creo MedicalAnnouncement

27/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220527:nRSa0033Na&default-theme=true

RNS Number : 0033N  Creo Medical Group PLC  27 May 2022

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Director/PDMR Shareholding

Chief Financial Officer purchases 70,000 shares; Non-Executive Chairman
purchases 15,435 shares

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that it has received
notification that Charles Spicer, Non-Executive Chairman of Creo, and Richard
Rees, Chief Financial Officer, have purchased ordinary shares of £0.001 each
in the Company ("Ordinary Shares").

 

Charles Spicer has purchased a total of 15,435 ordinary shares at a price of
97.18p per ordinary share. Following this transaction, Charles Spicer's total
direct interest in the Company held via his Self-Invested Personal Pension
("SIPP") is now 143,411 ordinary shares, representing approximately 0.08% of
the Company's issued share capital.

 

Richard Rees has purchased a total of 70,000 ordinary shares at a price of
96.75p per ordinary share; 21,400 of these shares are held via his SIPP.
Richard Rees' total direct interest in the Company is now 73,615 ordinary
shares, representing 0.04% of the Company's issued share capital.

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Charles Spicer

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Purchase of Ordinary Shares via SIPP

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     97.18p            15,435

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

      - Price

 e)   Date of the transaction                                      26 May 2022

 f)   Place of the transaction                                     London Stock Exchange

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Richard Rees

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

                                                                   Purchase of Ordinary Shares via SIPP

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   96.75p    48,600

                                                            96.75p    21,400

 

 d)   Aggregated information

      - Aggregated volume                                          70,000

      - Price                                                      £67,725.00

 e)   Date of the transaction                                      26 May 2022

 f)   Place of the transaction                                     London Stock Exchange

 

 

d)

 

Aggregated information

- Aggregated volume

70,000

- Price

£67,725.00

e)

 

Date of the transaction

 

 

26 May 2022

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEAESIRFIF